In these treatments for non-small cell lung cancer (NSCLC), immunotherapy using anti-programmed death-1 (PD-1) and its ligand PD-L1 antibody to target immune checkpoints is an effective method. The gene discussed is CD274; the disease is non-small cell lung carcinoma.